Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV

Download PDF Copy

Apr 15 2010

NewsGuard 100/100 Score

Pharmasset, Inc. (Nasdaq: VRUS) announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in patients with hepatitis C virus (HCV) genotype 1 who have not been treated previously. PSI-7977 is Pharmasset's nucleotide analog for the treatment of HCV. The Company announced the interim results in conjunction with the European Association for the Study of Liver Congress that commenced in Vienna, Austria on April 14, 2010.

Source:

Pharmasset, Inc.

Posted in: Drug Trial News | Disease/Infection News

Tags: Cancer, Chemotherapy, Efficacy, Hepatitis, Hepatitis A, Hepatitis B, Hepatitis B Virus, Hepatitis C, Hepatitis D, Hepatitis E, Immunodeficiency, Liver, Neutropenia, Nucleotide, Nucleotides, Peginterferon alfa, Prostate Cancer, Ribavirin, Virology, Virus

Comments (0)

Download PDF Copy

Suggested Reading

Study finds pistachios might help guard against vision loss

Study finds pistachios might help guard against vision loss

It's official! Men and women experience and manage pain differently

It's official! Men and women experience and manage pain differently

Brain-stimulation therapy at home reduces major depression symptoms

Brain-stimulation therapy at home reduces major depression symptoms

New glucose-sensitive insulin NNC2215 could transform diabetes care by lowering hypoglycemia risk

New glucose-sensitive insulin NNC2215 could transform diabetes care by lowering hypoglycemia risk

Transcranial ultrasound stimulation: A new frontier in noninvasive brain therapy

Transcranial ultrasound stimulation: A new frontier in noninvasive brain therapy

Researchers develop the first polymer-based therapeutic for Huntington’s disease

Researchers develop the first polymer-based therapeutic for Huntington’s disease

Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy

Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy

Study finds nirmatrelvir-ritonavir reduces severe COVID-19 and long COVID risks in high-risk patients

Study finds nirmatrelvir-ritonavir reduces severe COVID-19 and long COVID risks in high-risk patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Semaglutide vs. liraglutide: One-year weight loss efficacy in obesity and type 2 diabetes